Ethics questions swirl over US-backed infant vaccine timing study in Guinea-Bissau
TL;DR Summary
A U.S.-backed study in Guinea-Bissau aims to assess the health effects of hepatitis B vaccine dosing timing in about 14,000 infants, but it has sparked ethics concerns and confusion over whether the research will proceed, drawing criticism from scientists and former officials while U.S. agencies defend the project.
- RFK-backed infant vaccine study in Africa to proceed despite backlash, U.S. says The Washington Post
- Controversial US study on hepatitis B vaccines in Africa is cancelled The Guardian
- HHS Gave a $1.6 Million Grant to a Controversial Vaccine Study. These Emails Show How That Happened Rolling Stone
- CDC funding hepatitis vaccine study in African nation evokes Tuskegee study AJC.com
- Confusion Over 'Cancellation' Of Controversial Hepatitis B Trial In Guinea-Bissau Health Policy Watch
Reading Insights
Total Reads
0
Unique Readers
4
Time Saved
22 min
vs 23 min read
Condensed
99%
4,478 → 48 words
Want the full story? Read the original article
Read on The Washington Post